Nitroglycerin sublingual - Pohl-Boskamp

Drug Profile

Nitroglycerin sublingual - Pohl-Boskamp

Alternative Names: GoNitro; Nitrolingual Pumpspray

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pohl-Boskamp
  • Class Antineoplastics; Erectile dysfunction therapies; Heart failure therapies; Ischaemic heart disorder therapies; Nitro compounds; Organic nitrates; Small molecules; Sugar alcohols; Vasodilators
  • Mechanism of Action Guanylate cyclase stimulants; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris
  • Phase II Peripheral arterial occlusive disorders

Most Recent Events

  • 20 Nov 2017 Navamedic enters into a preliminary long-term distribution agreement with Pohl-Boskamp for the Nordic launch and commercialisation of Nitroglycerin sublingual
  • 20 Apr 2017 Phase-II clinical trials in Peripheral arterial occlusive disorders (In adults, In the elderly) in Germany (Sublingual) (EudraCT2016-004460-19)
  • 27 Sep 2016 Launched for Angina pectoris in USA (Sublingual, Powder)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top